BGI was established in 1999 as part of the world's very first Human Genome Project (HGP). Since then, we have built up over 20 years of genomics experience and developed a wide range of expert sequencing solutions, supporting researchers across the world pursue discovery across a fascinating variety of research.
For us, there is no project too big or too small. Please get in touch for a no obligation discussion or a free quote
BGI Genomics is a publicly listed commercial genomics company established in 1999. We provide a wide range of next generation sequencing services and bioinformatics services, and a broad portfolio of genetic tests to support medical institutions, research institutions, pharmaceutical companies and many other public and private partners.
Our business covers more than 100 countries and regions around the world, including more than 2,000 scientific research institutions and more than 2,300 medical institutions in China. We work with more than 3,000 institutions across Europe, North America and Asia Pacific.
Our expertise and scale allow us to provide quality data at extremely competitive pricing. Please visit our website to learn more about our solutions or get in touch directly via the form below.
DNBSEQ™ is a proprietary sequencing technology, first developed by MGI's Complete Genomics subsidiary in Silicon Valley, and can offer advantages in terms of lower amplification error rates and much lower duplication rates for some sequencing applications. In addition, studies have shown the index hopping rate in DNBSEQ™ platforms can be much lower when compared to that of other platforms.
CopyrightⒸ BGI 2024. All rights reserved. All product names, logos, and brands are property of their respective owners. All company, product and service names used in this email are for identification purposes only. Use of these names, logos, and brands does not imply endorsement. This email contains information on services or products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. We hereby disclose that this email communication is for commercial purposes. Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.